DM1-SMe |
| Catalog No.GC18254 |
DM1-SMe는 IMGN901에서 메이탄시노이드의 비접합 형태입니다. DM1-SMe는 인간 종양 세포주의 패널에서 DM1-SMe에 대해 IC50이 0.003에서 0.01nM 범위인 모 약물인 메이탄신보다 약 3-10배 더 강력합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 138148-68-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
DM1-SMe is an analog of mertansine with a thiomethane cap attached to the sulfhydryl group. It has in vitro activity against the pediatric preclinical testing program (PPTP) panel of cancer cell lines with IC50 values of 0.002 to >3 nM.
References:
[1]. Wood, A.C., Maris, J.M., Gorlick, R., et al. Initial testing (Stage 1) of the antibody-maytansinoid conjugate, IMGN901 (Lorvotuzumab mertansine), by the pediatric preclinical testing program Pediatr. Blood Cancer 60(11), 1860-1867 (2013).
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *